Biogen reported quarterly EPS of $3.57, beating the Zacks Consensus Estimate of $2.95 by $0.62, or about 21%. Earnings also improved from $3.02 per share a year ago, indicating year-over-year growth of roughly 18%. The result is a solid earnings beat for the biotech company and could support the shares modestly.
Biogen reported quarterly EPS of $3.57, beating the Zacks Consensus Estimate of $2.95 by $0.62, or about 21%. Earnings also improved from $3.02 per share a year ago, indicating year-over-year growth of roughly 18%. The result is a solid earnings beat for the biotech company and could support the shares modestly.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
